Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

NCT00782093 is registered in ClinicalTrials.gov with Ophthotech Corporation as lead sponsor.

NCT NCT00782093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00782093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration
Lead sponsor
Ophthotech Corporation
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2008
Completion date
June 30, 2012
Enrollment
63 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration